Menu
← Oncology Approval Tracker
FDA DECISION ·
Tukysa + trastuzumab
tucatinib + trastuzumab · Seagen
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with unresectable or metastatic RAS wild-type, HER2-positive colorectal cancer after progression on fluoropyrimidine, oxaliplatin and irinotecan-based therapy.
LAMPGEN ANALYSIS
Why it matters
The accelerated approval introduced a HER2-directed combination for a selected colorectal cancer subgroup.
What research teams should watch
Confirm both RAS and HER2 status, verify prior chemotherapy, and track confirmatory evidence.
PRIMARY RECORDS